PURPOSE: The management of patients with International Neuroblastoma Staging System (INSS) stage 3 neuroblastoma (NB) is not consistent worldwide. We describe a single centre approach at Memorial Sloan-Kettering Cancer Centre (MSKCC) from 1991 to 2007 that minimises therapy except for those patients with MYCN-amplified NB. METHODS: In this retrospective analysis of 69 patients, tumour MYCN was not amplified in 53 and amplified in 16. Event-free survival (EFS) and overall survival (OS) were determined by Kaplan-Meier analysis. RESULTS: Fourteen patients with non-MYCN-amplified tumours were treated with surgery alone (group A) and the remaining 39 (group B) with surgery following chemotherapy that was initiated and administered at non-MSKCC institutions. Chemotherapy was discontinued after surgery in 38/39 of the latter. The 10-year EFS and OS for all patients with MYCN-non-amplified NB were 74.9+/-16.9% and 92.6+/-5.5%, respectively. There was no difference in OS between groups A and B (p=0.2; 10-year OS for groups A and B was 84.6+/-14% and 97.1+/-2.9%, respectively). Patients with MYCN-amplified disease (group C) underwent dose-intensive induction, tumour resection and local radiotherapy: 13 achieved complete or very good partial remission, and 10 received myeloablative chemotherapy. 11/16 patients also received 3F8-based immunotherapy: 10 remain free of disease. The 10-year EFS and OS for patients with MYCN-amplified neuroblastoma treated with immunotherapy were both 90.9+/-8.7%. CONCLUSION: Patients with MYCN-non-amplified stage 3 NB can be successfully treated with surgery without the need for radiotherapy or continuation of chemotherapy. Combination of dose-intensive chemotherapy, surgery, radiotherapy and immunotherapy was associated with a favourable outcome for most patients with MYCN-amplified stage 3 NB.
PURPOSE: The management of patients with International Neuroblastoma Staging System (INSS) stage 3 neuroblastoma (NB) is not consistent worldwide. We describe a single centre approach at Memorial Sloan-Kettering Cancer Centre (MSKCC) from 1991 to 2007 that minimises therapy except for those patients with MYCN-amplified NB. METHODS: In this retrospective analysis of 69 patients, tumour MYCN was not amplified in 53 and amplified in 16. Event-free survival (EFS) and overall survival (OS) were determined by Kaplan-Meier analysis. RESULTS: Fourteen patients with non-MYCN-amplified tumours were treated with surgery alone (group A) and the remaining 39 (group B) with surgery following chemotherapy that was initiated and administered at non-MSKCC institutions. Chemotherapy was discontinued after surgery in 38/39 of the latter. The 10-year EFS and OS for all patients with MYCN-non-amplified NB were 74.9+/-16.9% and 92.6+/-5.5%, respectively. There was no difference in OS between groups A and B (p=0.2; 10-year OS for groups A and B was 84.6+/-14% and 97.1+/-2.9%, respectively). Patients with MYCN-amplified disease (group C) underwent dose-intensive induction, tumour resection and local radiotherapy: 13 achieved complete or very good partial remission, and 10 received myeloablative chemotherapy. 11/16 patients also received 3F8-based immunotherapy: 10 remain free of disease. The 10-year EFS and OS for patients with MYCN-amplified neuroblastoma treated with immunotherapy were both 90.9+/-8.7%. CONCLUSION:Patients with MYCN-non-amplified stage 3 NB can be successfully treated with surgery without the need for radiotherapy or continuation of chemotherapy. Combination of dose-intensive chemotherapy, surgery, radiotherapy and immunotherapy was associated with a favourable outcome for most patients with MYCN-amplified stage 3 NB.
Authors: S L Wolden; S V Gollamudi; B H Kushner; M LaQuaglia; K Kramer; N Rosen; S Abramson; N V Cheung Journal: Int J Radiat Oncol Biol Phys Date: 2000-03-01 Impact factor: 7.038
Authors: Caroline Laverdière; Nai-Kong V Cheung; Brian H Kushner; Kim Kramer; Shakeel Modak; Michael P LaQuaglia; Suzanne Wolden; Kirsten K Ness; James G Gurney; Charles A Sklar Journal: Pediatr Blood Cancer Date: 2005-09 Impact factor: 3.167
Authors: Giovanni Cecchetto; Veronique Mosseri; Bruno De Bernardi; Pierre Helardot; Tom Monclair; Elisa Costa; Ernst Horcher; Sylvia Neuenschwander; Paolo Tomà; Antonino Rizzo; Jean Michon; Keith Holmes Journal: J Clin Oncol Date: 2005-11-20 Impact factor: 44.544
Authors: K K Matthay; C Perez; R C Seeger; G M Brodeur; H Shimada; J B Atkinson; C T Black; R Gerbing; G M Haase; D O Stram; P Swift; J N Lukens Journal: J Clin Oncol Date: 1998-04 Impact factor: 44.544
Authors: J M Maris; M J Weiss; C Guo; R B Gerbing; D O Stram; P S White; M D Hogarty; E P Sulman; P M Thompson; J N Lukens; K K Matthay; R C Seeger; G M Brodeur Journal: J Clin Oncol Date: 2000-05 Impact factor: 44.544
Authors: D Strother; J van Hoff; P V Rao; E I Smith; R C Shamberger; E C Halperin; K J Murray; R P Castleberry Journal: Eur J Cancer Date: 1997-10 Impact factor: 9.162
Authors: N K Cheung; B H Kushner; M P LaQuaglia; K Kramer; P Ambros; I Ambros; M Ladanyi; J Eddy; M A Bonilla; W Gerald Journal: Eur J Cancer Date: 1997-10 Impact factor: 9.162
Authors: Frank Berthold; Joachim Boos; Stefan Burdach; Rudolf Erttmann; Günter Henze; Johann Hermann; Thomas Klingebiel; Bernhard Kremens; Freimut H Schilling; Martin Schrappe; Thorsten Simon; Barbara Hero Journal: Lancet Oncol Date: 2005-09 Impact factor: 41.316
Authors: K K Matthay; J G Villablanca; R C Seeger; D O Stram; R E Harris; N K Ramsay; P Swift; H Shimada; C T Black; G M Brodeur; R B Gerbing; C P Reynolds Journal: N Engl J Med Date: 1999-10-14 Impact factor: 91.245
Authors: Jaques van Heerden; Mariana Kruger; Tonya Esterhuizen; Marc Hendricks; Jennifer Geel; Ané Büchner; Gita Naidu; Jan du Plessis; Barry Vanemmenes; Ronelle Uys; G P Hadley Journal: Pediatr Surg Int Date: 2020-02-28 Impact factor: 1.827
Authors: Brian H Kushner; Shakeel Modak; Kim Kramer; Michael P LaQuaglia; Karima Yataghene; Ellen M Basu; Stephen S Roberts; Nai-Kong V Cheung Journal: Cancer Date: 2014-04-01 Impact factor: 6.860
Authors: Brian H Kushner; Michael P LaQuaglia; Shakeel Modak; Suzanne L Wolden; Ellen M Basu; Stephen S Roberts; Kim Kramer; Karima Yataghene; Irene Y Cheung; Nai-Kong V Cheung Journal: Oncotarget Date: 2017-08-24